A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FORTIFY
- Sponsors AbbVie; AbbVie Germany
- 14 Jun 2024 Planned End Date changed from 9 Jun 2026 to 14 May 2026.
- 14 Jun 2024 Planned primary completion date changed from 9 Jun 2026 to 14 May 2026.
- 17 May 2024 According to AbbVie Media Release, data from this trial will be presented at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C.